Partnered with Genentech and Microsoft, this biotech believes it can leverage its knowledge of the immune system into a $230M-plus IPO
Brothers Chad and Harlan Robins love big names, big numbers and big plans. And it’s all on big display in their newly filed S-1 for Adaptive Biotechnologies, which outlines a plan to leverage its work on cancer neoantigens and diagnostics into a whopping $230 million-plus IPO.
We’ve been seeing a wave of new IPO filings hit this market in the last few weeks, with some mixed but overall encouraging responses from investors. Alongside Adaptive, Morphic Therapeutics in the booming Cambridge/Boston hub has also decided to make the leap into the public market, posting an S-1 with an industry-standard $86 million raise penciled in as they hunt their next big injection of capital. Helmed by well-known biotech exec Praveen Tipirneni, the biotech has been building a platform based on work out of the lab of Harvard’s Tim Springer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.